



!flw

Please type a plus sign (+) inside this box



PTO/SB/21(08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/762,395
Filing Date	January 22, 2004
First Named Inventor	Tony Giordano
Group Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	26788-009

Total Number of Pages in This Submission

### ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
- ☐ Fee Attached
- ☐ Amendment / Response
- ☐ After Final
- ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/  
Incomplete Application
- ☐ Response to Missing  
Parts under 37 CFR  
1.52 or 1.53

- ☐ Assignment Papers  
(for an Application)
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a  
Provisional Application
- ☐ Power of Attorney, Revocation  
Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) \_\_\_\_\_

- ☐ After Allowance Communication  
to Group
- ☐ Appeal Communication to Board of  
Appeals and Interferences
- ☐ Appeal Communication to Group  
(Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Other Enclosure(s) (please  
identify below):
- Transmittal for IDS
  - PTO-1449 Form with  
Copies of References
  - Certificate of Mailing
  - Receipt Card

Remarks

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Kathleen W. Geiger, Registration No. 35,880
Signature	<i>Kathleen W. Geiger</i>
Date	Feb 8, 2005

### CERTIFICATE OF MAILING

I hereby certify that this correspondence is being sent via first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Denise Bierlein	Date	2/8/05
Signature	<i>Denise Bierlein</i>		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Giordano et al.

Serial No: 10/762,395

Filed: January 22, 2004

For: Use of Post-Transcriptional Gene  
Silencing for Identifying Nucleic Acid  
Sequences That Modulate the Function  
of a Cell

Case No.: 26788-009

Art Unit: 1645

Examiner: Unknown


Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
BEFORE MAILING DATE OF A FIRST OFFICE ACTION ON THE  
MERITS (37 CFR § 1.97(b)(3))**

Sir:

1. The Information Disclosure Statement transmitted herewith is being filed **before** the mailing date of the earliest occurrence of a first Office Action on the merits.
2. Applicant believes that no fee is due in accordance with the filing of this Information Disclosure Statement.
3. The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 501447 (Potter Anderson & Corroon LLP). A duplicate copy of this Petition is enclosed.

Respectfully submitted,

  
Kathleen W. Geiger  
Attorney for Applicant  
Reg. No. 35,880  
Telephone: (302) 984-6075  
Facsimile: (302) 658-1192

Date: Feb 03 '05

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //J.L./



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

In re Application of:

Giordano et al.

Serial No: 10/762,395

Filed: January 22, 2004

For: Use of Post-Transcriptional Gene  
Silencing for Identifying Nucleic Acid  
Sequences That Modulate the Function  
of a Cell

Case No.: 26788-009

Art Unit: 1645

Examiner: Unknown

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Listed on accompanying PTO-1449 Form are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. This statement is being filed within the time period specified in 37 CFR §1.97(b)(3). Applicant believes that no fee is required.

The Examiner is requested to consider and to make record herein of all the references cited by or to the Office in connection with the listed applications. In accordance with 37 C.F.R. §1.97(d) Applicant has not included copies of the U.S. Patents listed on the enclosed PTO-1449 Form.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.


This statement should not be construed as a representation that an exhaustive search has been made, or that there does not exist information more material to the examination of the present patent application. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is

further understood that the Examiner will review art of record in all 35 U.S.C. § 120 priority documents.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 501447 (Potter Anderson & Corroon). A duplicate copy of this pleading is enclosed.

Respectfully submitted,



Kathleen W. Geiger  
Attorney for Applicant

Reg. No. 35,880

Telephone: (302) 984-6075

Facsimile: (302) 658-1192

Date: Feb 2, 05



## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on February 8, 2005

Date

Signature

Denise Bierlein

Type or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Application No: 10/762,395

Filing Date: January 22, 2004

Title: Use of Post-Transcriptional Gene Silencing for Identifying Nucleic Acid Sequences That Modulate the Function of a Cell

Attorney Docket: 26788-009

- Transmittal Form
- Transmittal for Information Disclosure Statement
- Information Disclosure Statement
- PTO-1449 Form with Copies of References
- Receipt Card

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.:

**26788-009**

Application No.:

**10/762,395**Filing Date: **January 22, 2004**

First Named Inventor:

**Tony Giordano**

Examiner Name:

**Unknown**Art Group Unit: **1645****INFORMATION DISCLOSURE STATEMENT****BY APPLICANT***(See several sheets if necessary)***U.S. PATENT DOCUMENTS**

Examiner Initial	Cite No.	Office	Document Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication	Pages, Cols., Lines where, Relevant Passages Appear
		US	4,897,355		Eppstein et al.	01/30/1990	
		US	5,264,618		Felgner et al.	11/23/1993	
		US	5,279,833		Rose	01/18/1994	
		US	5,283,185		Epand et al.	02/01/1994	
		US	5,459,127		Felgner et al.	10/17/1995	
		US	5,880,276		Hammarskjold et al.	03/09/1999	
		US	5,932,241		Gorman	08/03/1999	

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Cite No.	Office	Document Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication	Pages, Cols., Lines where, Relevant Passages Appear	T
		WO	00/44914		Medical College of Georgia Research Institute Inc.	08/03/2000		
		WO	00/63364		American Home Products Corporation	10/26/2000		
		WO	01/68836	A2	Genetica, Inc.	09/20/2001		

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

		Cronin et al., <i>The Lac Operator-Repressor System is Functional in the Mouse</i> , Genes & Development, 2001, Volume 15, pp. 1506 -1517
		Khlebnikov et al., <i>Regulatable Arabinose-Inducible Gene Expression System With Consistent Control in All Cells of a Culture</i> , Journal of Bacteriology, Dec. 2000, Vol. 182 No. 24, pp. 7029-7034
		RheoGene, <a href="http://www.rheogene.com">www.rheogene.com</a>
		Wang et al., Development of Gene-Switch Transgenic Mice That Inducibly Express Transforming Growth Factor Beta $\beta$ in the Epidermis, Proc. Natl. Acad. Sci. USA, July 1999, Vol. 96, pp 8483-8488

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: <b>26788-009</b>	Application No.: <b>10/762,395</b>
<b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		Filing Date: <b>January 22, 2004</b>	
		First Named Inventor:	
		<b>Tony Giordano</b> Examiner Name: <b>Unknown</b>	Art Group Unit: <b>1645</b>

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Rendahl et al., Tightly Regulated Long-Term Erythropoietin Expression In Vivo Using Tet-Inducible Recombinant Adeno-Associated Viral Vectors, Human Gene Therapy, January 20, 2002, Vol. 13, pp. 335-342
	Lamartina et al., Stringent Control of Gene Expression In Vivo by Using Novel Doxycycline-Dependent Trans-Activators, Human Gene Therapy, January 20, 2002, Vol. 13, pp. 199-210
	Jaramillo et al., The Interferon System: A Review With Emphasis on the Role of PKR in Growth Control, Cancer Investigation, 1995, Vol. 13 (3), pp. 327-338
	Platet et al., A New Bioassay Using Transient Transfection for Invasion-Related Gene Analysis, Invasion & Metastasis, 1998/99, Vol. 18, pp. 198-208
	Harper et al., Analysis of the Neurotrophic Effects of GPI-1046 on Neuron Survival and Regeneration in Culture and In Vivo, Neuroscience, 1999, Vol. 88 No. 1, pp. 257-267
	Tomaselli et al., Interactions of a Neuronal Cell Line (PC12) With Laminin, Collagen IV, and Fibronectin: Identification of Integrin-Related Glycoproteins Involved in Attachment and Process Outgrowth, The Journal of Cell Biology, November 1987, Vol. 105, pp. 2347-2358
	Marrack et al., Genomic-Scale Analysis of Gene Expression in Resting and Activated T Cells, Current Opinion in Immunology, 2000, Vol. 12, pp. 206-209
	Harkin et al., Uncovering Functionally Relevant Signaling Pathways Using Microarray-Based Expression Profiling, The Oncologist, 2000, Vol. 5, pp. 501-507
	Pelizzari et al., Quantitative Analysis of DNA Array Autoradiographs, Nucleic Acids Research, 2000, Vol. 28 No. 22, pp. 4577-4581
	Marx, DNA Arrays Reveal Cancer in its Many Forms, Science, September 8, 2000, Vol. 289, Issue 5485, pp. 1670-1672
	Satoh et al., Site-Specific Integration of an Adeno-Associated Virus Vector Plasmid Mediated by Regulated Expression of Rep Based on Cre-loxP Recombination, Journal of Virology, November 2000, pp. 10631-10638
	Trinh et al., Site-Specific and Directional Gene Replacement Mediated by Cre Recombinase, Journal of Immunological Methods, 2000, Vol. 244, pp. 185-193
	Serov et al., Genetic Modification of Mammalian Genome at Chromosome Level, An. Acad. Bras. Ci., 2000, Vol. 72(3), pp. 389-398
	Grez et al., New Vectors for Gene Therapy, Stem Cells, 1998, Vol. 16 (Suppl 1), pp. 235-243
	Haren et al., Integrating DNA: Transposases and Retroviral Integrases, Annu. Rev. Microbiol., 1999, Vol. 53, pp. 245-281
	Baer et al., Transcriptional Properties of Genomic Transgene Integration Sites Marked by Electroporation or Retroviral Infection, Biochemistry, 2000, Vol. 39, pp. 7041-7049
	Follenzi et al., Gene Transfer by lentiviral Vectors is Limited by Nuclear Translocation and Rescued by HIV-1 Pol Sequences, Nature Genetics, June 2000, Vol. 25, pp. 217-222
	Hindmarsh et al., Retroviral DNA Integration, Microbiology and Molecular Biology Reviews, December 1999, Vol. 63 No. 4, pp. 836-843

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: <b>26788-009</b>	Application No.: <b>10/762,395</b>
<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		Filing Date: <b>January 22, 2004</b>	
		First Named Inventor:  <b>Tony Giordano</b>	
		Examiner Name: <b>Unknown</b>	Art Group Unit: <b>1645</b>

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Darquet et al., Minicircle: An Improved DNA Molecule For In Vitro And In Vivo Gene Transfer, Gene Therapy, 1999, Vol. 6, pp. 209-218
	Yu et al., A New System to Place Single Copies of Genes, Sites and LacZ Fusions on the Escherichia Coli Chromosome, Gene, 1998, Vol. 223, pp. 77-81
	Darquet et al., A New DNA Vehicle For Nonviral Gene Delivery: Supercoiled Minicircle, Gene Therapy, 1997, Vol. 4, pp. 1341-1349
	Koch et al., Site-Specific Integration of Targeted DNA Into Animal Cell Genomes, Gene, 2000, Vol. 249, pp. 135-144
	Liu et al., Efficient Cre-loxP-Induced Mitotic Recombination in Mouse Embryonic Stem Cells, Nature Genetics, January 2002, Vol. 30, pp. 66-72
	Awatramani et al., An Flip Indicator Mouse Expressing Alkaline Phosphatase from the ROSA26 Locus, Nature Genetics, November 2001, Vol. 29, pp. 257-259
	Heidmann et al., Reduction of Cre Recombinase Toxicity in Proliferating Drosophila Cells by Estrogen-Dependent Activity Regulation, Dev. Genes Evol., 2001, Vol. 211, pp. 458-465
	Schaft et al., Efficient FLP Recombination in Mouse ES Cells and Oocytes, Genesis, 2001, Vol. 31, p. 6-10
	Lorbach et al., Site-Specific Recombination in Human Cells Catalyzed by Phage $\lambda$ Integrase Mutants, Mol. Biol., 2000, Vol. 296, pp. 1175-1181
	Bushman et al., Tethering Human Immunodeficiency Virus Type 1 Preintegration Complexes to Target DNA Promotes Integration at Nearby Sites, Journal of Virology, January 1997, pp. 458-464
	Reik et al., Silence Across The Border, Nature, May 2000, Vol. 405, pp. 408-409
	Berger et al., Chromatin Goes Global, Molecular Cell, August 2001, Vol. 8, pp. 263-268
	Shibata et al., Homologous Genetic Recombination as an Intrinsic Dynamic Property of a DNA Structure Induced by RecA/Rad51-Family Proteins: A Possible Advantage of DNA over RNA as Genomic Material, PNAS, July 7, 2001, Vol. 98 No. 15, pp. 8425-8432
	Muyrers et al., Techniques: Recombinogenic Engineering – New Options For Cloning And Manipulating DNA, TRENDS in Biochemical Sciences, May 2001, Vol. 26 No. 5, pp. 325-331
	Paul et al., Expression of E. Coli RecA Targeted to Mitochondria of Human Cells, Mutation Research, 2001, Vol. 486, pp. 11-19
	Shcherbakova et al., Overexpression of Bacterial RecA Protein Stimulates Homologous Recombination in Somatic Mammalian Cells, Mutation Research, 2000, Vol. 459, pp. 65-71
	Forster et al., Tetracycline-Inducible Expression Systems With Reduced Basal Activity in Mammalian Cells, Nucleic Acids Research, 1999, Vol. 27 No. 2, pp. 708-710
	Pachuk et al., Chain Reaction Cloning: A One-Step Method For Directional Ligation of Multiple DNA Fragments, Gene, 2000, Vol. 243, pp. 19-25
	Romano et al., Inhibition of Double-Stranded RNA-Dependent Protein Kinase PKR by Vaccinia Virus E3: Role of Complex Formation and the E3 N-Terminal Domain, Molecular and Cellular Biology, December 1998, Vol. 18 No. 12, pp. 7304-7316



Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: <b>26788-009</b>	Application No.: <b>10/762,395</b>
<b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		Filing Date: <b>January 22, 2002</b>	
		First Named Inventor:	
		<b>Tony Giordano</b> Examiner Name: <b>Unknown</b>	
		Art Group Unit: <b>1645</b>	

**OTHER DOCUMENTS** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	Pachuk et al., DNA Vaccines – Challenges in Delivery, Current Opinion in Molecular Therapeutics, 2000, Vol. 2(2), pp. 188-198
	Pachuk et al., Characterization of a New Class of DNA Delivery Complexes Formed by the Local Anesthetic Bupivacaine, Biochimica et Biophysica Acta, 2000, Vol. 1468, pp. 20-30
	Ghislain et al., The Interferon-Inducible Stat2: Stat1 Heterodimer Preferentially Binds In Vitro to a Consensus Element Found in the Promoters of a Subset of Interferon-Stimulated Genes, Journal of Interferon and Cytokine Research, 2001, Vol. 21, pp. 379-388
	Igoucheva et al., Targeted Single-Base Correction by RNA-DNA Oligonucleotides, Human Gene Therapy, November 2000, Vol. 11, pp. 2307-2312
	Woodhouse et al., General Mechanisms of Metastasis, Cancer Supplement, October 1997, Vol. 80, No. 8, pp. 1529-1537
	Zhang et al., Binding of Double-Stranded RNA to Protein Kinase PKR is Required for Dimerization And Promotes Critical Autophosphorylation Events in the Activation Loop, The Journal of Biological Chemistry, 2001, Vol. 276 No. 27, pp. 24946-24958
EXAMINER	/Jeffrey Lundgren/
DATE CONSIDERED 01/08/2009	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	